These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30131194)

  • 21. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
    De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
    Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health and economic impact of rotavirus vaccination in GAVI-eligible countries.
    Kim SY; Sweet S; Slichter D; Goldie SJ
    BMC Public Health; 2010 May; 10():253. PubMed ID: 20470426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights from global data for use of rotavirus vaccines in India.
    Rao TS; Arora R; Khera A; Tate JE; Parashar U; Kang G;
    Vaccine; 2014 Aug; 32 Suppl 1():A171-8. PubMed ID: 25091672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis for rotavirus vaccine decision-making: How can we best inform evolving and complex choices in vaccine product selection?
    Pecenka C; Debellut F; Bar-Zeev N; Anwari P; Nonvignon J; Clark A
    Vaccine; 2020 Feb; 38(6):1277-1279. PubMed ID: 31859203
    [No Abstract]   [Full Text] [Related]  

  • 27. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
    Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh.
    Sarker AR; Sultana M; Mahumud RA; Van Der Meer R; Morton A
    Hum Vaccin Immunother; 2018 Jan; 14(1):189-198. PubMed ID: 29099653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of rotavirus vaccination programs in developing countries.
    Hallowell BD; Tate J; Parashar U
    Expert Rev Vaccines; 2020 Jun; 19(6):529-537. PubMed ID: 32543239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of rotavirus vaccination in Turkey.
    Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
    J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rotavirus vaccines: development, current issues and future prospects.
    Cunliffe NA; Bresee JS; Hart CA
    J Infect; 2002 Jul; 45(1):1-9. PubMed ID: 12217724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
    Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
    J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study.
    Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Atherly D
    Lancet Glob Health; 2021 Jul; 9(7):e942-e956. PubMed ID: 33891885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A cost-effectiveness analysis on universal infant rotavirus vaccination strategy in China].
    Sun SL; Gao YQ; Yin J; Zhuang GH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Feb; 37(2):238-42. PubMed ID: 26917523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
    Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
    PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031.
    Nonvignon J; Atherly D; Pecenka C; Aikins M; Gazley L; Groman D; Narh CT; Armah G
    Vaccine; 2018 Nov; 36(47):7215-7221. PubMed ID: 29223486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rotavirus vaccines: targeting the developing world.
    Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
    J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
    Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
    Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
    Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
    Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of routine infant rotavirus immunisation program in Japan.
    Hoshi SL; Kondo M; Okubo I
    Hum Vaccin Immunother; 2017 May; 13(5):1115-1125. PubMed ID: 27763810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.